254:
hyperactivation . Rather, prolonged viral replication and leucocyte hyperactivation phases may occur concurrently, and this work suggested that some patients may benefit from anti-viral therapy when on mechanical ventilation (currently not endorsed by clinical guidelines). Further work demonstrated, for the first time, the ability to systematically culture SARS-CoV-2 from cough aerosol with a particle diameter < 10uM (particles that can remain suspended in air for several hours and that can be inhaled deeply into the lung) . These data provided the ‘missing link’ to solidify the notion that aerosol-based infectiousness of COVID-19 is a dominant method of transmission (the heterogeneity in infectiousness of participants also supports the super-spreader hypothesis). Up to this point the final proof needed to justify major public health spending to implement transmission-interrupting interventions (essentially improved ventilation) was lacking.
242:
drug-resistant strains of TB were not less infectious due to genetic ‘fitness cost’, as previously anticipated, but that there was ongoing widespread transmission of such strains within community settings . This has highlighted the important contribution of TB to the burgeoning antimicrobial resistance problem confronting the world (~30% of the contribution to the estimated global cost of antimicrobial resistance will be due to drug-resistant TB) . The work has facilitated the acceleration of containment strategies and newer regimens for drug-resistant TB . Related novel work, for the first time, demonstrated differential drug penetration into human lung TB cavities and its contribution to drug resistance amplification .
1004:
30:
1009:
234:
become even more important in the post COVID-19 era due to the worsening under-detection of TB . In contradistinction to traditional accuracy-based evaluation methodology, his work has focused on the application of randomised-controlled trial design for the evaluation of new TB diagnostic tools, to tease out impact on patient important outcomes . This together with other studies
642:, amongst others. He has been part of several advisory and adjudication panels including those of the WHO, NIH, EU and the Wellcome Trust (Discovery Grant panel). Dheda is a former president of the South African Thoracic Society, is the founder and co-director of the charity, Free of TB, which provides support and healthcare to poor and needy persons afflicted with TB.
249:
complex that involved the installation of live mycobacteria into the lungs of human volunteers , and development of the ‘first in man’ transcriptomic map of human TB cavities (using explanted lung samples) that has provided foundational knowledge to unravel the genesis of human TB-associated lung
233:
Dheda’s work has catalysed the reconfiguration of global public health policy from one of passive TB case-finding (self-reporting by patients) to one of active case-finding (community-based unearthing of cases), and he has pioneered novel models outlining how this could be accomplished . This has
253:
The lung centric work was leveraged to better understand the immunopathogenesis of COVID-19. A new immune-phenotype of prolonged lung-specific viral replication was described debunking the notion that viral replication ended after the first week of symptoms followed by a phase of leucocyte
241:
His work has had substantial impact on global health, including the transmission and management of drug-resistant TB that has informed management decisions by national TB programmes, including screening and infection control policies for health care workers . His work indicated that highly
229:
TB is one of the biggest killers of mankind, remains the foremost infectious diseases killer globally, and has made a resurgence in the UK and the
European Region, which now reports the highest burden of confirmed multi-drug-resistant TB cases annually.
314:. Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV- positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial.
470:, et al. Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study.
548:. SARS-CoV-2 viral replication persists in the human lung for several weeks after onset of symptomatic severe COVID-19 and is associated with attenuated pulmonary immunity and variant-specific clinical sequalae.
284:. Feasibility, accuracy and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised controlled trial.
245:
Scientific breakthroughs improving the understanding of TB immunopathogenesis have included the development and validation of the ‘first in man’ human lung challenge model for
585:
1080:
626:
581:
298:, et al. The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions.
563:. Frequency, kinetics and determinants of viable SARS-CoV-2 in bioaerosols from ambulatory COVID-19 patients infected with the Beta, Delta or Omicron variants.
1075:
268:. Comparison of two diagnostic intervention packages for community-based active case finding for tuberculosis: an open-label randomized controlled trial.
238:
has led to the development of new standards of care for tuberculosis diagnostics and their application to clinical practice (and in specific subgroups).
1046:
168:
507:
2018. 198 (9):1208-1219. (First and senior author; IF = 24.7; cited 95 times since publication ; cited 123 times since publication ). CITATION CLASSIC
477:
2017. 2600(16):30433-7. (First and senior author; IF = 76.2; cited 95 times since publication ; cited 136 times since publication ). CITATION CLASSIC.
373:. High Incidence of Hospital Admissions with Multidrug Resistant and Extensively Drug Resistant Tuberculosis among South African Health Care Workers.
290:. 2014; S0140-6736(13)62073-5. (Senior author; IF = 168.9; cited 342 times since publication ; cited 520 times since publication ). CITATION CLASSIC.
459:
2014; 383 (9924). 1230-1239. (Senior author; IF = 168.9; cited 192 times since publication ; cited 290 times since publication ). CITATION CLASSIC
1085:
651:
320:
2016:140-6736(15) 01092-2. (Senior author; IF = 168.9; cited 184 times since publication ; cited 265 times since publication ). CITATION CLASSIC.
200:
428:. 2013. 8(1): e54587. (Senior author; IF = 3.7; cited 139 times since publication ; cited 217 times since publication ). CITATION CLASSIC.
345:. 2013; 10(10), e1001536. (Senior author; IF = 15.8; cited 138 times since publication ; cited 209 times since publication ). CITATION CLASSIC.
354:. Accuracy and impact of Xpert MTB/RIF for the diagnosis of smear-negative or sputum-scarce tuberculosis using bronchoalveolar lavage fluid.
407:. Bacterial and host determinants of cough aerosol culture positivity in patients with drug-resistant versus drug-susceptible tuberculosis.
380:
2010;153(8):516-22. (Senior author; IF = 39.2; cited 157 times since publication ; cited 256 times since publication ). CITATION CLASSIC
790:
361:
2013. 68(11):1043-51. (Senior author; IF = 10; cited 82 times since publication ; cited 130 times since publication ). CITATION CLASSIC
339:. Diagnostic accuracy of quantitative PCR (Xpert MTB/RRIF) for tuberculosis meningitis in a high burden setting: a prospective study.
898:
156:
1090:
492:
2018. 51 (5). (Senior author; IF = 24.3; cited 69 times since publication ; cited 104 times since publication ). CITATION CLASSIC.
1039:
593:
486:. Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa.
437:. An All-Oral 6-Month Regimen for Multidrug-Resistant TB (the NExT Study): A Multicenter, Randomized Controlled Trial.
500:, et al. Gumbo T. Drug-Penetration Gradients Associated with Acquired Drug Resistance in Patients with Tuberculosis.
1095:
589:
822:
1032:
605:
519:. A Human Lung Challenge Model to Evaluate the Safety and Immunogenicity of PPD and Live Bacillus Calmette-Guérin.
876:
160:
804:
453:. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study.
533:, et al. Spatial Network Mapping of Pulmonary Multidrug-Resistant Tuberculosis Cavities Using RNA Sequencing.
919:
601:
180:
83:
765:
656:
613:
184:
176:
87:
118:
London School of
Hygiene and Tropical Medicine, University of Cape Town, University College London
638:
204:
624:
Dheda serves or has served on the editorial board of several high impact journals including the
422:. What is the Cost of Diagnosis and Management of Drug Resistant Tuberculosis in South Africa?
1070:
745:
392:. Incidence of occupational latent tuberculosis infection in South African healthcare workers.
214:
164:
1065:
172:
8:
730:
1020:
850:
681:
661:
64:
Scientific contributions to the field of respiratory infections including tuberculosis.
838:
1003:
842:
854:
834:
609:
706:
1016:
734:
1059:
196:
192:
945:
814:
937:
846:
29:
208:
110:
Respiratory
Medicine; Immunology; Antimicrobial Resistance; Tuberculosis
632:
597:
78:
791:"UCT's leading TB researcher receives top international science prize"
188:
899:"UCT to spearhead research into antibiotic resistance | Cape Times"
964:
1015:
This South
African biographical article related to medicine is a
596:
Scientific
Achievement Award (Platinum). He has been profiled in
218:
1008:
749:
588:
Scientific
Leadership Award. Other awards have included the
305:
2022. 10(6):603-622. (First and senior author; IF = 102.64)
972:
627:
American
Journal of Respiratory and Critical Care Medicine
582:
International Union
Against Tuberculosis and Lung Disease
325:
https://classic.clinicaltrials.gov/ct2/show/NCT04303104
444:
2022. 15;205(10):1214-1227. (Senior author; IF = 24.7)
584:
Scientific Award, and the 2018 European Union-funded
525:. 2020. 201(10):1277-1291. (Senior author; IF = 24.7)
203:(LSHTM) with an extra-mural joint appointment at the
250:cavitation, which remains largely unexplained .
1081:Members of the Academy of Science of South Africa
616:, a high-profile news programme in South Africa.
398:. 2015. 45(5):1364-73. (Senior author; IF = 24.3)
1057:
652:London School of Hygiene & Tropical Medicine
213:He is a global research leader in the field of
201:London School of Hygiene and Tropical Medicine
1076:Academic staff of the University of Cape Town
1040:
946:"President of South African Thoracic Society"
973:"Director and founder of Free of TB charity"
592:, the NSTF BHP-Billiton Research award, and
539:. 2019. (First and senior author; IF = 24.7)
330:https://clinicaltrials.gov/study/NCT05220163
1047:
1033:
28:
575:
1086:University of the Witwatersrand alumni
1058:
215:TB immunopathogenesis and TB diagnosis
820:
56:Researcher; professor; medical doctor
998:
221:of 100 and Scopus h-Index of 79 .
13:
590:Harry Oppenheimer Fellowship Award
413:. 2020. (Senior author; IF = 82.9)
207:(UCT), where he is a Professor of
14:
1107:
970:
943:
874:
1007:
1002:
952:. South African Thoracic Society
275:2023. (Senior author; IF = 82.9)
1091:African medical biography stubs
912:
891:
257:
868:
797:
783:
758:
739:
724:
699:
674:
141:Charities founded and directed
1:
839:10.1016/S0140-6736(14)60140-9
667:
619:
1019:. You can help Knowledge by
823:"Rising star of pulmonology"
805:"NSTF Winners Press Release"
766:"The Union Scientific Prize"
748:publications indexed by the
128:Number of registered patents
7:
645:
633:Lancet Respiratory Medicine
224:
84:University of Witwatersrand
40:1969 (age 54–55)
10:
1112:
1096:South African people stubs
997:
135:Spin-off companies founded
657:University College London
536:Am J Respir Crit Care Med
522:Am J Respir Crit Care Med
503:Am J Respir Crit Care Med
440:Am J Respir Crit Care Med
147:
114:
106:
98:
93:
88:University College London
77:
72:
68:
60:
52:
44:
36:
27:
20:
920:"TB bomb set to expolde"
887:– via PressReader.
752:bibliographic database.
733:publications indexed by
821:Dheda, Keertan (2014).
754:(subscription required)
639:British Medical Journal
551:Am J Resp Crit Care Med
205:University of Cape Town
576:Awards and recognition
187:), born in 1969, is a
48:British; South African
662:Keertan Dheda | LSHTM
566:Nature Communications
209:Respiratory Medicine.
707:"Prof Keertan Dheda"
580:Dheda received the
73:Academic background
877:"Man on a mission"
711:UCT Lung Institute
544:Tomasicchio M,..,
1028:
1027:
950:pulmonology.co.za
571:
555:
554:. 2023. In Press.
540:
526:
511:
493:
478:
463:
445:
429:
414:
399:
384:
369:O'Donnell MR,..,
365:
346:
331:
326:
321:
306:
301:Lancet Respir Med
291:
276:
151:
150:
1103:
1049:
1042:
1035:
1011:
1006:
999:
989:
988:
986:
984:
971:Dheda, Keertan.
968:
962:
961:
959:
957:
944:Dheda, Keertan.
941:
935:
934:
932:
930:
916:
910:
909:
907:
905:
895:
889:
888:
886:
884:
875:Dheda, Keertan.
872:
866:
865:
863:
861:
818:
812:
811:
809:
801:
795:
794:
787:
781:
780:
778:
776:
762:
756:
755:
743:
737:
728:
722:
721:
719:
717:
703:
697:
696:
694:
692:
678:
559:Jaumdally S,..,
558:
543:
529:
514:
496:
481:
466:
449:Pietersen E,..,
448:
432:
417:
402:
387:
376:Ann Internal Med
368:
349:
334:
329:
324:
309:
294:
280:Theron, G, ...,
279:
263:
193:Mycobacteriology
32:
18:
17:
1111:
1110:
1106:
1105:
1104:
1102:
1101:
1100:
1056:
1055:
1054:
1053:
995:
993:
992:
982:
980:
969:
965:
955:
953:
942:
938:
928:
926:
918:
917:
913:
903:
901:
897:
896:
892:
882:
880:
873:
869:
859:
857:
819:
815:
807:
803:
802:
798:
789:
788:
784:
774:
772:
764:
763:
759:
753:
744:
740:
729:
725:
715:
713:
705:
704:
700:
690:
688:
682:"Keertan Dheda"
680:
679:
675:
670:
648:
622:
578:
570:2023. In Press.
473:Lancet Resp Med
410:Nature Medicine
271:Nature Medicine
264:Esmail A, ...,
260:
247:M. tuberculosis
237:
227:
138:
131:
124:
119:
23:
12:
11:
5:
1109:
1099:
1098:
1093:
1088:
1083:
1078:
1073:
1068:
1052:
1051:
1044:
1037:
1029:
1026:
1025:
1012:
991:
990:
963:
936:
911:
890:
879:. Press Reader
867:
813:
796:
782:
757:
738:
735:Google Scholar
723:
698:
672:
671:
669:
666:
665:
664:
659:
654:
647:
644:
621:
618:
577:
574:
573:
572:
556:
541:
527:
512:
494:
482:Olayanju O,.,
479:
464:
446:
430:
415:
400:
385:
366:
350:Theron G, ..,
347:
332:
327:
322:
307:
292:
277:
259:
256:
235:
226:
223:
149:
148:
145:
144:
116:
112:
111:
108:
107:Sub-discipline
104:
103:
100:
96:
95:
91:
90:
81:
75:
74:
70:
69:
66:
65:
62:
61:Known for
58:
57:
54:
50:
49:
46:
42:
41:
38:
34:
33:
25:
24:
21:
9:
6:
4:
3:
2:
1108:
1097:
1094:
1092:
1089:
1087:
1084:
1082:
1079:
1077:
1074:
1072:
1071:Living people
1069:
1067:
1064:
1063:
1061:
1050:
1045:
1043:
1038:
1036:
1031:
1030:
1024:
1022:
1018:
1013:
1010:
1005:
1001:
1000:
996:
978:
974:
967:
951:
947:
940:
925:
921:
915:
900:
894:
878:
871:
856:
852:
848:
844:
840:
836:
833:(9915): 403.
832:
828:
824:
817:
806:
800:
792:
786:
771:
767:
761:
751:
747:
746:Keertan Dheda
742:
736:
732:
731:Keertan Dheda
727:
712:
708:
702:
687:
683:
677:
673:
663:
660:
658:
655:
653:
650:
649:
643:
641:
640:
635:
634:
629:
628:
617:
615:
614:Carte Blanche
611:
607:
603:
599:
595:
591:
587:
583:
569:
567:
562:
557:
553:
552:
547:
542:
538:
537:
532:
528:
524:
523:
518:
515:Davids M,..,
513:
510:
506:
504:
499:
495:
491:
490:
489:Eur Respir J.
485:
480:
476:
474:
469:
465:
462:
458:
457:
452:
447:
443:
441:
436:
433:Esmail A,..,
431:
427:
426:
421:
418:Pooran A,..,
416:
412:
411:
406:
403:Theron G,..,
401:
397:
396:
391:
386:
383:
379:
377:
372:
367:
364:
360:
358:
353:
348:
344:
343:
342:PloS Medicine
338:
333:
328:
323:
319:
318:
313:
308:
304:
302:
297:
293:
289:
288:
283:
278:
274:
272:
267:
262:
261:
255:
251:
248:
243:
239:
231:
222:
220:
216:
211:
210:
206:
202:
198:
197:Global health
194:
190:
186:
182:
178:
174:
170:
166:
162:
158:
155:
154:Keertan Dheda
146:
142:
139:
136:
132:
129:
125:
123:
122:H-index = 100
117:
113:
109:
105:
101:
97:
94:Academic work
92:
89:
85:
82:
80:
76:
71:
67:
63:
59:
55:
53:Occupation(s)
51:
47:
43:
39:
35:
31:
26:
22:Keertan Dheda
19:
16:
1021:expanding it
1014:
994:
981:. Retrieved
979:. Free of TB
977:freeoftb.com
976:
966:
954:. Retrieved
949:
939:
927:. Retrieved
923:
914:
902:. Retrieved
893:
881:. Retrieved
870:
858:. Retrieved
830:
826:
816:
799:
785:
773:. Retrieved
769:
760:
741:
726:
714:. Retrieved
710:
701:
689:. Retrieved
685:
676:
637:
631:
625:
623:
602:Business Day
579:
565:
564:
560:
550:
549:
545:
535:
534:
530:
521:
520:
516:
508:
502:
501:
497:
488:
487:
483:
472:
471:
467:
460:
455:
454:
450:
439:
438:
434:
424:
423:
419:
409:
408:
404:
395:Eur Respir J
394:
393:
389:
388:Adams S,..,
381:
375:
374:
370:
362:
356:
355:
351:
341:
340:
336:
335:Patel VB,.,
316:
315:
311:
310:Peter JG,.,
300:
299:
295:
286:
285:
281:
270:
269:
265:
258:Publications
252:
246:
244:
240:
232:
228:
212:
153:
152:
140:
134:
133:
127:
126:
121:
120:
115:Institutions
15:
1066:1969 births
604:newspaper,
456:The Lancet.
317:The Lancet.
45:Nationality
1060:Categories
827:The Lancet
716:3 November
691:3 November
668:References
636:, and the
620:Leadership
598:The Lancet
287:The Lancet
99:Discipline
79:Alma mater
770:The Union
189:Professor
855:40910739
847:24485575
646:See also
425:PLoS One
225:Research
217:(Google
102:Medicine
561:Dheda K
546:Dheda K
531:Dheda K
517:Dheda K
498:Dheda K
484:Dheda K
468:Dheda K
451:Dheda K
435:Dheda K
420:Dheda K
405:Dheda K
390:Dheda K
371:Dheda K
352:Dheda K
337:Dheda K
312:Dheda K
296:Dheda K
282:Dheda K
266:Dheda K
219:h-index
199:at the
983:29 May
956:29 May
929:5 July
924:News24
904:5 July
883:29 May
860:29 May
853:
845:
775:6 July
750:Scopus
612:, and
610:News24
600:, the
357:Thorax
167:(SA),
851:S2CID
808:(PDF)
686:LSHTM
586:EDCTP
157:MBBCh
1017:stub
985:2018
958:2018
931:2018
906:2018
885:2018
862:2018
843:PMID
777:2018
718:2021
693:2021
195:and
185:Lond
181:FRCP
177:Lond
169:FCCP
161:Wits
37:Born
835:doi
831:383
606:IOL
594:MRC
191:of
179:),
173:PhD
165:FCP
163:),
143:: 1
137:: 1
130:: 6
1062::
975:.
948:.
922:.
849:.
841:.
829:.
825:.
768:.
709:.
684:.
630:,
608:,
171:,
86:,
1048:e
1041:t
1034:v
1023:.
987:.
960:.
933:.
908:.
864:.
837::
810:.
793:.
779:.
720:.
695:.
568:.
509:.
505:.
475:.
461:.
442:.
382:.
378:.
363:.
359:.
303:.
273:.
236:,
183:(
175:(
159:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
